Donald Zoz, MD, Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim explains the mechanism of action of BI 1015550 to treat idiopathic pulmonary fibrosis (IPF). 

IPF is a chronic, progressive, fibrosing lung disease with few treatment options and a poor prognosis. Common symptoms of IPF include shortness of breath and difficulty performing daily activities, such as walking and talking. 

As Dr. Zoz explains, BI 1015550 is a phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects. The orphan drug is currently being investigated in two phase III clinical trials – one for IPF and one for other progressive fibrosing interstitial lung diseases. At present, there are no approved treatments for IPF that can delay disease progression of IPF. 

To learn more about the clinical trials, visit FIBRONEER-IPF and FIBRONEER-ILD.

To learn more about IPF and other rare lung disease, visit